While this development is encouraging, any reversal agent will have come too late to help those who have already been harmed by Xarelto bleeding.
New York, New York (PRWEB) January 14, 2015
As Xarelto lawsuits (http://www.xareltolawsuit2015.com/ ) continue to move forward in federal court, Bernstein Liebhard LLP notes that the development of an antidote to reverse the internal bleeding sometimes associated with the blood thinner is now one step closer to reality. According to Reuters, the intravenous drug, known as andexanet alfa, has met the main goal of reversing the anticoagulant effects of Xarelto in a late-stage study. Data from the trial indicated that the reversal of Xarelto bleeding was immediate among healthy volunteers aged 50-75 years. More details from the study are expected to be released later this year.*
“Our Firm is currently representing Xarelto lawsuit plaintiffs who allegedly experienced uncontrollable bleeding due to the blood thinner, and the lack of an approved antidote to reverse this complication is an important issue in these claims. While this development is encouraging, any reversal agent will have come too late to help those who have already been harmed by Xarelto bleeding,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free, no-obligation Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
Xarelto was approved by the U.S. Food & Drug Administration in 2011, and is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery. Like any blood thinner, Xarelto may cause patients to experience internal bleeding. However, there is currently no approved antidote to reverse this potentially deadly complication.**
Court records indicate that dozens of Xarelto lawsuits are currently pending in a federal multidistrict litigation now underway in U.S. District Court, Eastern District of Louisiana, where all federally-filed claims alleging injury due to the medication have been consolidated for coordinated pretrial proceedings. All of these lawsuits similarly allege that Xarelto’s manufacturers wrongly marketed the medication as a superior alternative to warfarin, a blood thinner that has been on the market for decades. Among other things, the lawsuits point out that while there is currently no approved reversal agent for Xarelto bleeding, hemorrhaging associated with warfarin can be stopped via the administration of Vitamin K. (In Re: Xarelto Products Liability Litigation, No. 2592)
Individuals who suffered uncontrollable episodes of internal bleeding allegedly associated with Xarelto may be entitled to take legal action against the drug’s manufacturers. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*reuters.com/article/2015/01/09/us-portola-pharma-study-idUSKBN0KI1DR20150109, Reuters, January 9, 2015
**fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP